<DOC>
	<DOCNO>NCT00729651</DOCNO>
	<brief_summary>To demonstrate efficacy/safety Fosamax Plus D</brief_summary>
	<brief_title>Efficacy Safety Study Fosamax Plus D Postmenopausal Women With Osteoporosis ( 0217A-263 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Patient agree apply sunscreen limit sunlightexposure 1 hour per day study Patient diagnose osteoporosis Patient postmenopausal 6 month Patient contraindication take oral bisphosphonates Patient eligible dual energy xray absorptiometry spine hip Patients esophageal dysfunction Patients sit stand least 30 minute Patients malignant disease active systemic disease 5 year prior participate trial Patients diseases bone mineral metabolism besides osteoporosis receive therapy affect bone metabolism calcium metabolism Patients history major gastrointestinal disease ( peptic ulcer , malabsorption , esophageal disease , gastritis , gastroduodenitis , etc . ) within last 6 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>